US gives green light to Guidant's chromium stent
This article was originally published in Clinica
The FDA has approved Guidant's cobalt chromium coronary stent for sale in the US. The PMA for the Multi-link Vision system signals something of a regulatory rehabilitation for the device, which was recalled from release in Europe and Australia in April following a technical problem with the delivery system.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.